

**Referenzen:**

**1** Wang Z-X, et al. Cancer Cell 2022;40(3):277-288.

**2** Chen Y-X, et al. Ann Oncol 2026. Final OS JUPITER-06.  
DOI:10.1016/j.annonc.2026.01.005.

**3** Chen Q-Y, Long-term overall survival following-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (JUPITER-02). Presented at: ESMO Asia Annual Meeting 2025; 5-7 Dec 2025, Singapore.